{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:24:11Z","timestamp":1792801451840,"version":"4.5.0"},"reference-count":136,"publisher":"Elsevier BV","issue":"2","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.pharmthera.2013.09.006","type":"journal-article","created":{"date-parts":[[2013,9,28]],"date-time":"2013-09-28T17:35:00Z","timestamp":1380389700000},"page":"150-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":642,"title":["Existing and potential therapeutic uses for N-acetylcysteine: The need for conversion to intracellular glutathione for antioxidant benefits"],"prefix":"10.1016","volume":"141","author":[{"given":"Gordon F.","family":"Rushworth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian L.","family":"Megson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2013.09.006_bb0005","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1212\/WNL.57.8.1515","article-title":"Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease","volume":"57","author":"Adair","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2125.2005.02523.x","article-title":"N-acetylcysteine \u2014 passe-partout or much ado about nothing?","volume":"61","author":"Aitio","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0015","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0891-5849(99)00175-6","article-title":"Gene expression and the thiol redox state","volume":"27","author":"Arrigo","year":"1999","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0020","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/0891-5849(89)90066-X","article-title":"The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid","volume":"6","author":"Aruoma","year":"1989","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0025","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MCA.0b013e328351aacc","article-title":"Intrarenal application of N-acetylcysteine for the prevention of contrast medium-induced nephropathy in primary angioplasty","volume":"23","author":"Aslanger","year":"2012","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0030","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/S0735-1097(03)00487-X","article-title":"A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study","volume":"41","author":"Baker","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0035","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0041-008X(86)90331-5","article-title":"Experimental chelation therapy in chromium, lead, and boron intoxication with N-acetylcysteine and other compounds","volume":"83","author":"Banner","year":"1986","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0040","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0014-5793(78)80105-7","article-title":"Reduced and oxidized glutathione efflux from liver","volume":"86","author":"Bartoli","year":"1978","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0045","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s11064-009-9962-3","article-title":"The role of intracellular glutathione in inorganic mercury-induced toxicity in neuroblastoma cells","volume":"34","author":"Becker","year":"2009","journal-title":"Neurochem Res"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0050","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1164\/ajrccm.156.6.9706065","article-title":"Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis: adjunctive therapy to maintenance immunosuppression","volume":"156","author":"Behr","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0055","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.biopsych.2008.04.022","article-title":"N-acetyl cysteine for depressive symptoms in bipolar disorder\u2014a double-blind randomized placebo-controlled trial","volume":"64","author":"Berk","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0060","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.biopsych.2008.03.004","article-title":"N-acetyl cysteine as a glutathione precursor for schizophrenia\u2014a double-blind, randomized, placebo-controlled trial","volume":"64","author":"Berk","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0065","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jad.2011.06.005","article-title":"The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial","volume":"135","author":"Berk","year":"2011","journal-title":"J Affect Disord"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb9000","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.bbrc.2005.10.098","article-title":"Depressed glutathione synthesis precedes oxidative stress and atherogenesis in Apo-E-\/- mice","volume":"338","author":"Biswas","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0070","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.2174\/092986705774462987","article-title":"Chelators as antidotes of metal toxicity: therapeutic and experimental aspects","volume":"12","author":"Blanusa","year":"2005","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0075","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF00606662","article-title":"Pharmacokinetics of N-acetylcysteine in man","volume":"31","author":"Borgstrom","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0080","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10534-005-4020-3","article-title":"DMPS and N-acetylcysteine induce renal toxicity in mice exposed to mercury","volume":"19","author":"Brandao","year":"2006","journal-title":"Biometals"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0085","first-page":"383","article-title":"N-acetylcysteine fails to prevent renal dysfunction and oxidative stress after noniodine contrast media administration during percutaneous coronary interventions","volume":"120","author":"Buyukhatipoglu","year":"2010","journal-title":"Pol Arch Med Wewn"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0090","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1164\/ajrccm\/139.2.370","article-title":"Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis","volume":"139","author":"Cantin","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0095","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1172\/JCI113005","article-title":"Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis","volume":"79","author":"Cantin","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0100","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0300-8932(10)70004-X","article-title":"N-acetylcysteine: short-term clinical benefits after coronary angiography in high-risk renal patients","volume":"63","author":"Carbonell","year":"2010","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0105","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2165\/00002018-200022020-00005","article-title":"Utility of acetylcysteine in treating poisonings and adverse drug reactions","volume":"22","author":"Chyka","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0110","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/bdd.2510080408","article-title":"Gastrointestinal metabolism of N-acetylcysteine in the rat, including an assay for sulfite in biological systems","volume":"8","author":"Cotgreave","year":"1987","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0115","first-page":"73","article-title":"No penetration of orally administered N-aceylcysteine into bronchoalveolar lavage fluid","volume":"70","author":"Cotgreave","year":"1987","journal-title":"Eur J Respir Dis"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0120","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0006-2952(91)90674-T","article-title":"The metabolism of N-acetylcysteine by human endothelial cells","volume":"42","author":"Cotgreave","year":"1991","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15563650500394571","article-title":"Acetaminophen poisoning: an evidence-based consensus guideline for out-of-hospital management","volume":"44","author":"Dart","year":"2006","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0130","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/2047-783X-14-8-352","article-title":"A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis","volume":"14","author":"Dauletbaev","year":"2009","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jcf.2004.03.005","article-title":"Glutathione and glutathione peroxidase in sputum samples of adult patients with cystic fibrosis","volume":"3","author":"Dauletbaev","year":"2004","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0140","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/carcin\/6.12.1735","article-title":"In vivo effects of N-acetylcysteine on glutathione metabolism and on the biotransformation of carcinogenic and\/or mutagenic compounds","volume":"6","author":"De Flora","year":"1985","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0145","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/carcin\/5.4.505","article-title":"In vitro effects of N-acetylcysteine on the mutagenicity of direct-acting compounds and procarcinogens","volume":"5","author":"De Flora","year":"1984","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0150","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/carcin\/22.7.999","article-title":"Mechanisms of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related end-points","volume":"22","author":"De Flora","year":"2001","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0155","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1046\/j.1365-2362.2000.00736.x","article-title":"N-acetylcysteine replenishes glutathione in HIV infection","volume":"30","author":"De Rosa","year":"2000","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0160","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1503\/jpn.100057","article-title":"N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action","volume":"36","author":"Dean","year":"2011","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0165","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMoa042976","article-title":"High-dose acetylcysteine in idiopathic pulmonary fibrosis","volume":"353","author":"Demedts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0170","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.freeradbiomed.2004.06.011","article-title":"Human glutamate cysteine ligase gene regulation through the electrophile response element","volume":"37","author":"Dickinson","year":"2004","journal-title":"Free Radical Biol Med"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0175","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/ndt\/gfh261","article-title":"Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury","volume":"19","author":"Drager","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0180","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1136\/thorax.55.suppl_2.S51","article-title":"Oxidant stress in asthma","volume":"55","author":"Dworski","year":"2000","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0185","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/MAJ.0b013e31821fbdbc","article-title":"Management of idiopathic pulmonary fibrosis","volume":"341","author":"Fioret","year":"2011","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0190","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/0002-9343(91)90296-A","article-title":"Use of N-acetylcysteine in clinical toxicology","volume":"91","author":"Flanagan","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0195","doi-asserted-by":"crossref","first-page":"L113","DOI":"10.1152\/ajplung.1999.277.1.L113","article-title":"Abnormal glutathione transport in cystic fibrosis airway epithelia","volume":"277","author":"Gao","year":"1999","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0200","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/FJC.0b013e3181b6e77b","article-title":"Evaluation of the antioxidant properties of N-acetylcysteine in human platelets: prerequisite for bioconversion to glutathione for antioxidant and antiplatelet activity","volume":"54","author":"Gibson","year":"2009","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2840-10-43","article-title":"Therapeutic potential of N-acetylcysteine as an antiplatelet agent in patients with type-2 diabetes","volume":"10","author":"Gibson","year":"2011","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0210","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.bcp.2012.09.010","article-title":"N-acetylcysteine derivative with an unusual pharmacokinetic feature and remarkable antioxidant potential","volume":"84","author":"Giustarini","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0215","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ehj.2003.11.011","article-title":"Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography: a randomized controlled trial and review of the current literature","volume":"25","author":"Goldenberg","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0220","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3109\/15563650.2013.775292","article-title":"Treating acetaminophen overdose: thresholds, costs and uncertainties","volume":"51","author":"Gosselin","year":"2013","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0230","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3109\/15563650.2011.568491","article-title":"Intravenous paracetamol\u2014an international perspective of toxicity","volume":"49","author":"Gray","year":"2011","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0225","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1521-0391.2009.00027.x","article-title":"N-acetylcysteine (NAC) in young marijuana users: An open-label pilot study","volume":"19","author":"Gray","year":"2010","journal-title":"Am J Addict"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0235","doi-asserted-by":"crossref","first-page":"218","DOI":"10.5811\/westjem.2012.4.6885","article-title":"Oral and intravenous acetylcysteine for treatment of acetaminophen toxicity: a systematic review and meta-analysis","volume":"14","author":"Green","year":"2013","journal-title":"West J Emerg Med"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0240","first-page":"3264","article-title":"Oxidative stress and cardiovascular disease","volume":"96","author":"Griendling","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0245","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S0891-5849(99)00176-8","article-title":"Biologic and pharmacologic regulation of mammalian glutathione synthesis","volume":"27","author":"Griffith","year":"1999","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0250","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jcin.2011.09.019","article-title":"Contemporary use and effectiveness of N-acetylcysteine in preventing contrast-induced nephropathy among patients undergoing percutaneous coronary intervention","volume":"5","author":"Gurm","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0255","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/10715769609149066","article-title":"Vitamin C: Antioxidant or pro-oxidant in vivo","volume":"25","author":"Halliwell","year":"1996","journal-title":"Free Radic Res"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0260","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1006\/abbi.1998.0914","article-title":"Protection by vitamin C of loss of vitamin E in cultured rat hepatocytes","volume":"359","author":"Halpner","year":"1998","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0265","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.biopsych.2012.01.014","article-title":"A randomised controlled pilot trial of oral N-acetylcysteine in children with autism","volume":"71","author":"Hardan","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0270","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/0140-6736(90)91388-Q","article-title":"Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine","volume":"335","author":"Harrison","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0275","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1093\/emboj\/cdg332","article-title":"Evidence that reactive oxygen species do not mediate NF-kB activation","volume":"22","author":"Hayakawa","year":"2003","journal-title":"EMBO J"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0280","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1073\/pnas.94.5.1967","article-title":"Glutathione deficiency is associated with impaired survival in HIV disease","volume":"94","author":"Herzenberg","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0285","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2165\/00003088-199120020-00004","article-title":"Clinical pharmacokinetics of N-acetylcysteine","volume":"20","author":"Holdiness","year":"1991","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0290","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.2169\/internalmedicine.51.7894","article-title":"N-acetylcysteine for the prevention of contrast-induced nephropathy in the emergency department","volume":"51","author":"Hsu","year":"2012","journal-title":"Intern Med"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0295","first-page":"962","article-title":"Laboratory and clinical evaluation of the mucolytic properties of acetylcysteine","volume":"96","author":"Hurst","year":"1967","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0300","doi-asserted-by":"crossref","first-page":"695","DOI":"10.4070\/kcj.2011.41.12.695","article-title":"N-acetylcysteine for prevention of contrast-induced nephropathy: a narrative review","volume":"41","author":"Jo","year":"2011","journal-title":"Korean Circ J"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0305","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3390\/nu4101399","article-title":"Dysregulation of glutathione homeostasis in neurodegenerative diseases","volume":"4","author":"Johnson","year":"2012","journal-title":"Nutrients"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0310","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00128-010-9982-3","article-title":"Protective role of thiol chelators against dimethylmercury induced toxicity in male rats","volume":"84","author":"Joshi","year":"2010","journal-title":"Bull Environ Contam Toxicol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0315","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.2146\/ajhp060050","article-title":"Comparison of oral and iv acetylcysteine in the treatment of acetaminophen poisoning","volume":"63","author":"Kanter","year":"2006","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0320","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.neuro.2006.01.010","article-title":"Glutathione modulation influences methyl mercury induced neurotoxicity in primary cell cultures of neurones and astrocytes","volume":"27","author":"Kaur","year":"2006","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0325","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.pharmthera.2005.10.015","article-title":"Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy","volume":"111","author":"Kirkham","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0330","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.biopsych.2008.10.040","article-title":"The role of cystine-glutamate exchange in nicotine dependence in rats and humans","volume":"65","author":"Knackstedt","year":"2009","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0335","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ijcard.2010.10.041","article-title":"Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS\u2014A multicenter prospective controlled trial","volume":"155","author":"Koc","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0340","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00213-005-0246-6","article-title":"N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive\u2013compulsive disorder","volume":"184","author":"Lafleur","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0345","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1161\/01.CIR.97.19.1930","article-title":"Glutathione-related antioxidant defenses in human atherosclerotic plaques","volume":"97","author":"Lapenna","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0350","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/sj.npp.1301624","article-title":"Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients","volume":"33","author":"Lavoie","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0355","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1089\/ars.2007.2013","article-title":"Endothelial dysfunction: From molecular mechanisms to measurement, clinical implications, and therapeutic opportunities","volume":"10","author":"Le Brocq","year":"2008","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0360","doi-asserted-by":"crossref","first-page":"329643","DOI":"10.1155\/2011\/329643","article-title":"N-acetylcysteine supplementation controls total antioxidant capacity, creatinine kinase, lactate, and tumour necrotic factor-alpha against oxidative stress induced by graded exercise in sedentary men","volume":"2011","author":"Leelarungrayub","year":"2011","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0365","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1089\/152308601317203594","article-title":"GSH is required to recycle ascorbic acid in cultured liver cell lines","volume":"3","author":"Li","year":"2001","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0370","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0891-5849(98)00048-3","article-title":"Thiol chelation of Cu2+ by dihydrolipoic acid prevents human low density lipoprotein peroxidation","volume":"25","author":"Lodge","year":"1998","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0375","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1517\/14656566.2013.758250","article-title":"The evolving pharmacotherapy of pulmonary fibrosis","volume":"14","author":"Lota","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0380","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/archneur.1995.00540300031009","article-title":"Randomized double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis","volume":"52","author":"Louwerse","year":"1995","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0385","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.mam.2008.05.005","article-title":"Regulation of glutathione synthesis","volume":"30","author":"Lu","year":"2009","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0390","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/00099308409035080","article-title":"Treatment of acute methylmercury ingestion by hemodialysis with N-acetylcysteine (Mucomyst) infusion and 2,3-dimercaptopropane sulfonate","volume":"22","author":"Lund","year":"1984","journal-title":"J Toxicol Clin Toxicol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0395","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1093\/ndt\/gfn090","article-title":"The molecular mechanisms of the attenuation of cisplatin-induced acute renal failure by N-acetylcysteine in rats","volume":"23","author":"Luo","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0400","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/CPM.0b013e3182350bb4","article-title":"Current and future therapies for idiopathic pulmonary fibrosis","volume":"18","author":"Maher","year":"2011","journal-title":"Clin Pulm Med"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0405","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.pnpbp.2006.10.001","article-title":"An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study","volume":"31","author":"Mardikian","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0410","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/00002030-199711000-00014","article-title":"Low serum thiol levels predict shorter times-to-death among HIV-infected injecting drug users","volume":"11","author":"Marmor","year":"1997","journal-title":"AIDS"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0415","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2337\/dc07-2251","article-title":"Long-term N-acetylcysteine and l-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes","volume":"31","author":"Martina","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0420","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1006\/abbi.1997.0473","article-title":"Protection and recycling of alpha-tocopherol in human erythrocytes by intracellular ascorbic acid","volume":"349","author":"May","year":"1998","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0425","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0009-9120(97)00094-5","article-title":"Diabetes-induced alterations in platelet metabolism","volume":"30","author":"Mazzanti","year":"1997","journal-title":"Clin Biochem"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0430","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1148\/radiol.12121823","article-title":"Intravenous contrast material-induced nephropathy: causal or coincident phenomenon?","volume":"267","author":"McDonald","year":"2013","journal-title":"Radiology"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0435","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.nut.2011.07.024","article-title":"Cysteine: the Fun-Ke nutraceutical","volume":"28","author":"McPherson","year":"2012","journal-title":"Nutrition"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0440","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1146\/annurev.bi.52.070183.003431","article-title":"Glutathione","volume":"52","author":"Meister","year":"1983","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0445","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1164\/ajrccm.152.3.7663783","article-title":"Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals","volume":"152","author":"Meyer","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0450","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1183\/09031936.94.07030431","article-title":"The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis","volume":"7","author":"Meyer","year":"1994","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0455","doi-asserted-by":"crossref","first-page":"15506","DOI":"10.1074\/jbc.M608361200","article-title":"Vitamin C is an essential antioxidant that enhances survival of oxidatively stressed human vascular endothelial cells in the presence of a vast molar excess of glutathione","volume":"282","author":"Montecinos","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0460","first-page":"93","article-title":"Long-term oral acetylcysteine in chronic bronchitis. A double-blind controlled study","volume":"61","author":"Multicentre Study Group","year":"1980","journal-title":"Eur J Respir Dis"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0465","first-page":"1101","article-title":"Management of paracetamol poisoning: The old and the new","volume":"6","author":"Nambiar","year":"2012","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0470","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1164\/ajrccm.162.6.2003049","article-title":"The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis","volume":"162","author":"Nicholson","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0475","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/BF01061422","article-title":"Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine","volume":"34","author":"Olsson","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0480","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/15563650802245497","article-title":"Risk factors and mechanisms of anaphylactoid reactions to acetylcysteine in acetaminophen overdose","volume":"46","author":"Pakravan","year":"2008","journal-title":"Clin Toxicol"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2013.09.006_bb0485","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s00270-005-0196-8","article-title":"The clinical epidemiology of contrast-induced nephropathy","volume":"28","author":"Parfrey","year":"2005","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0490","first-page":"245","article-title":"Pharmacokinetic and pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent during a phase I trial","volume":"4","author":"Pendyala","year":"1995","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0495","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00005344-199807000-00016","article-title":"Oral administration of the antioxidant, N-acetylcysteine, abrogates diabetes-induced endothelial dysfunction","volume":"32","author":"Pieper","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0500","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0006-2952(03)00504-5","article-title":"The changing faces of glutathione, a cellular protagonist","volume":"66","author":"Pompella","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0505","first-page":"1","article-title":"Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: Systematic review","volume":"332","author":"Poole","year":"2001","journal-title":"Br Med J"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0510","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1136\/bmj.2.6198.1097","article-title":"Intravenous N-acetylcysteine: The treatment of choice for paracetamol poisoning","volume":"2","author":"Prescott","year":"1979","journal-title":"Br Med J"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0515","first-page":"432","article-title":"Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine","volume":"2","author":"Prescott","year":"1977","journal-title":"Br Med J"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0520","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0140-6736(76)92842-7","article-title":"Cysteamine, methionine, and penicillamine in the treatment of paracetamol poisoning","volume":"308","author":"Prescott","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0525","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisolone, azathioprine, and N-acetylcysteine for pulmonary fibrosis","volume":"366","author":"Raghu","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0530","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0891-5849(00)00215-X","article-title":"Regulation of redox glutathione levels and gene transcription in lung inflammation: therapeutic approaches","volume":"28","author":"Rahman","year":"2000","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0535","doi-asserted-by":"crossref","first-page":"614","DOI":"10.2174\/138161212799315984","article-title":"New therapies in cystic fibrosis","volume":"18","author":"Ratjen","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0540","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/COC.0b013e31822e006d","article-title":"Transtympanic injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: A feasible method with promising efficacy","volume":"36","author":"Riga","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0545","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0891-5849(97)00231-1","article-title":"Macrophage glutathione content and glutathione peroxidase activity are inversely related to cell-mediated oxidation of LDL: in vitro and in vivo studies","volume":"24","author":"Rosenblat","year":"1998","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0550","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/MOP.0b013e3280109b90","article-title":"Advances in cystic fibrosis therapies","volume":"18","author":"Rowe","year":"2006","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0555","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/thx.2005.045591","article-title":"British Thoracic Society Study on cryptogenic fibrosing alveolitis: response to treatment and survival","volume":"62","author":"Rudd","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0560","series-title":"British National Formulary","year":"2012"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0565","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/hep.23267","article-title":"Novel mechanisms of protection against hepatotoxicity in mice by glutathione and N-acetylcysteine","volume":"51","author":"Saito","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0570","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1016\/j.bbagen.2013.04.016","article-title":"The chemistry and biological activities of N-acetylcysteine","volume":"1830","author":"Samuni","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0580","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/15563650802665587","article-title":"Adverse reactions associated with acetylcysteine","volume":"47","author":"Sandilands","year":"2009","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6904-12-3","article-title":"Mechanisms for an effect of acetylcysteine on renal function after exposure to radio-graphic contrast material: study protocol","volume":"12","author":"Sandilands","year":"2012","journal-title":"BMC Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0585","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/hrt.2004.053579","article-title":"N-acetylcysteine for prevention of radiocontrast induced nephrotoxicity: The importance of dose and route of administration","volume":"91","author":"Shalansky","year":"2005","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0590","first-page":"721","article-title":"The in vitro reduction in viscosity of human tracheobronchial secretions by acetylcysteine","volume":"90","author":"Sheffner","year":"1964","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0595","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.arr.2012.10.004","article-title":"Oxidative stress and cancer: an overview","volume":"12","author":"Sosa","year":"2013","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0600","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/978-1-4614-5441-0_21","article-title":"Oxidative stress in diabetes","volume":"771","author":"Stadler","year":"2012","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0605","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1034\/j.1399-3003.2000.16b12.x","article-title":"The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review","volume":"16","author":"Stey","year":"2000","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0610","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1038\/mt.2011.160","article-title":"N-acetylcysteine enhances cystic fibrosis sputum penetration an airway gene transfer by highly compacted DNA nanoparticles","volume":"19","author":"Suk","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1145\/2525528.2525529","article-title":"Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomised, controlled trials","volume":"8","author":"Sun","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0620","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.addr.2009.03.002","article-title":"Anti-oxidants for therapeutic use: Why are only a few drugs in clinical use?","volume":"61","author":"Suzuki","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0625","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/030006058301100505","article-title":"Acetylcysteine (Fabrol) in chronic bronchitis \u2014 a study on general practice","volume":"11","author":"Tattersall","year":"1983","journal-title":"J Int Med Res"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0630","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1073\/pnas.0511304103","article-title":"High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis","volume":"103","author":"Tirouvanziam","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0635","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1007\/s00125-012-2685-z","article-title":"N-acetylcysteine inhibits platelet\u2013monocyte conjugation in patients with type 2 diabetes with depleted intraplatelet glutathione: a randomised controlled trial","volume":"55","author":"Treweeke","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0640","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.freeradbiomed.2013.05.050","article-title":"The thiol pool in human plasma: the central contribition of albumin to redox processes","volume":"65","author":"Turell","year":"2013","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0645","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1681\/ASN.2004060458","article-title":"N-acetylcysteine decreases angiotensin II receptor binding in vascular smooth muscle cells","volume":"16","author":"Ullian","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0650","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/jnci\/92.12.977","article-title":"EUROSCAN, a randomised trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer","volume":"92","author":"van Zandwijk","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0655","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1586\/ecp.12.15","article-title":"Criteria for acetylcysteine treatment and clinical outcomes after paracetamol poisoning","volume":"5","author":"Waring","year":"2012","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0660","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/15563650701864760","article-title":"Lower incidence of anaphylactoid reactions to N-acetylcysteine in patients with high acetaminophen concentrations after overdose","volume":"46","author":"Waring","year":"2008","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0665","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0891-5849(99)00051-9","article-title":"Reactivity pf biologically important thiol compounds with superoxide and hydrogen peroxide","volume":"27","author":"Winterbourne","year":"1999","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb9005","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1124\/jpet.105.086645","article-title":"Transport of N-acetylcysteine s-conjugates of methylmercury in Madin-Darby canine kidney cells stably transfected with human isoform of organic anion transporter 1","volume":"314","author":"Zalups","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2013.09.006_bb0670","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1681\/ASN.V94551","article-title":"Participation of mercuric conjugates of cysteine, homocysteine, and N-acetylcysteine in mechanisms involved in the renal tubular uptake of inorganic mercury","volume":"9","author":"Zalups","year":"1998","journal-title":"J Am Soc Nephrol"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725813001952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725813001952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,6]],"date-time":"2022-03-06T22:58:50Z","timestamp":1646607530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725813001952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":136,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0163725813001952"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2013.09.006","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Existing and potential therapeutic uses for N-acetylcysteine: The need for conversion to intracellular glutathione for antioxidant benefits","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2013.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}